Kuo, Yu-WeiYu-WeiKuoLee, Cheng-YungCheng-YungLeeYI-TING HSIEHCHUNG-MAY YANGTZYY-CHANG HOTSO-TING LAICHANG-HAO YANG2024-12-042024-12-042024-09-28https://scholars.lib.ntu.edu.tw/handle/123456789/723579This study evaluates the impact of anti-vascular endothelial growth factor (anti-VEGF) treatment on neovascular age-related macular degeneration (nAMD) with and without pigment epithelial detachment (PED) over a one-year period. Conducted at a tertiary referral center in Taiwan, this retrospective analysis included 88 eyes treated with intravitreal aflibercept injections. Patients were categorized into four groups based on the presence or absence of PED at baseline and 12 months post-treatment. Significant reductions in central macular thickness (CMT) and PED height were observed, although no statistical difference was found in best-corrected visual acuity (BCVA). The presence or type of PED did not negatively impact visual outcomes. Among nAMD patients with persistent PED throughout the first year of anti-VEGF treatment, linear regression analysis showed that mixed-type PED revealed poor final BCVA compared to those with serous PED. The analysis also identified older age and poorer initial BCVA as predictors of less favorable visual outcomes. This study highlights the effectiveness of anti-VEGF therapy in real-world settings and offers insights into factors influencing visual outcomes for nAMD patients with PED.enanti-vascular endothelial growth factorbest-corrected visual acuityneovascular age-related macular degenerationoptical coherence tomographyretinal pigment epithelial detachmentjournal article10.3390/jpm1410104139452548